Project description
Combatting superbugs with drug resistance breakthrough
Antimicrobial resistance presents a grave healthcare threat, with multidrug-resistant gram-negative bacteria causing an increasing number of infections. The urgent need for new antibacterial drugs is amplified by economic challenges hindering development. A key concern is the compromised effectiveness of vital β-lactam antibiotics due to drug-resistant bacteria producing β-lactamase enzymes. In this context, the EIC-funded sbli-ant3310 project emerges as a beacon of hope. By combining meropenem, a well-known antibiotic, with ANT3310, an innovative serine-β-lactamase inhibitor, the project aims to tackle hospital-acquired infections caused by drug-resistant pathogens. Preclinical trials have demonstrated remarkable efficacy against top-priority pathogens. Pending successful clinical trials, ANT3310 is anticipated to be licensed and potentially generate over EUR 10 billion in sales by 2042.
Objective
Antimicrobial resistance (AMR) due to multidrug-resistant Gram-negative bacteria are an increasingly serious healthcare threat, exacerbated by major economic issues underlying the development of new antibacterial drugs. The effectiveness of β-lactam antibiotics, the most important class of antibacterial agents, is impaired by the production of β-lactamase enzymes by drug-resistant bacteria.
We are developing a combination of a well-known antibiotic (meropenem) and ANT3310, our proprietary, best-in-class serine-β-lactamase inhibitor, intended for the treatment of hospital-acquired infections caused by drug-resistant pathogens. Our treatment has been pre-clinically proven to be efficacious against all three pathogens deemed a critical priority by the World Health Organization (WHO).
We will conduct three clinical trials and next out-license ANT3310 to a pharmaceutical partner. We expect market approval by 2029 and that ANT3310 will generate over €10bn in sales within 13 years.
Fields of science
- natural sciencesbiological sciencesmicrobiologybacteriology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibiotics
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistancemultidrug resistance
- medical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsenzymes
Keywords
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
31670 Labege
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.